Featured Research

from universities, journals, and other organizations

How a cancer-killing gene may actually work

Date:

May 27, 2014

Source:

University of Colorado Denver

Summary:

Scientists armed with a supercomputer and a vast trove of newly collected data on the body's most potent "tumor suppressor" gene have created the best map yet of how the gene works, an accomplishment that could lead to new techniques for fighting cancers, which are adept at disabling the gene in order to thrive.

Share This

Scientists armed with a supercomputer and a vast trove of newly collected data on the body's most potent "tumor suppressor" gene have created the best map yet of how the gene works, an accomplishment that could lead to new techniques for fighting cancers, which are adept at disabling the gene in order to thrive.

Related Articles

Scientists from the University of Colorado Cancer Center and the University of Colorado Boulder used a new technology to tease out how the p53 gene -- which is responsible for recognizing damaged DNA in cells and then marking them for death -- is actually able to suppress tumors by determining what other genes p53 regulates. The study, published in the journal eLife, describes dozens of new genes directly regulated by p53.

The study authors say further research can explore which of these genes are necessary for p53's cancer-killing effect, how cancer cells evade these p53-activated genes, and how doctors may be able to moderate cancer cells' ability to stay safe from these genetic attempts at suppression.

The exhaustively studied p53 gene -- which has been the subject of 50,000 papers over more than 30 years of research -- is the most commonly inactivated gene in cancers. When p53 acts, cells are stopped or killed before they can survive, grow, replicate and cause cancer.

As such, all cancers must deal with p53's anti-tumor effects. Generally, there are two ways that cancer cells do this: by mutating p53 directly or by making a protein called MDM2, which stops p53 from functioning

The current study explores cancer cells' second strategy of blocking p53 function by producing the protein MDM2. Researchers have reasoned that treating a patient with an MDM2 inhibitor should allow p53 to restart its anti-cancer activities.

"MDM2 inhibitors, which are through phase I human trials, effectively activate p53 but manage to kill only about one-in-20 tumors," said Joaquνn Espinosa, an investigator at the CU Cancer Center, an associate professor of molecular, cellular and developmental biology at CU-Boulder, and the paper's co-senior author. "The question is why. What else is happening in these cancer cells that allow them to evade p53?"

The answer is in what are called "downstream" effects of this gene, Espinosa said. The gene p53 doesn't act against cancer alone. Instead, it is the master switch that sets in motion a cascade of genetic events that lead to the destruction of cancer cells. And until now, it was unclear exactly which other genes were directly activated by p53.

The imperfect knowledge of p53's effects isn't for lack of research interest. Researchers have written thousands of papers exploring p53's targets and, in fact, many genetic targets are previously known. Most of these studies determine genetic targets by measuring levels of RNA.

When a gene is activated, it creates a protein. But between the gene and its protein product is the measurable step of RNA -- the more gene-specific RNA, the more often a gene's informational blueprint is carried to the cell's manufacturing centers, and the more protein is eventually made. Researchers measure RNA to see which genes are being turned up or down by any other gene.

"But the problem is, measuring overall RNA levels is like looking in a huge bucket full of water -- you see the water but you don't really know where it came from. And imagine you are dripping water into this bucket -- it takes a long time for those drips to create a measurable change in the overall water level," Espinosa said.

Also, it's very difficult with traditional methods to tell whether increased RNA is a direct effect of a gene or whether more RNA in the bucket is a product of two- or three-steps removed signaling. The p53 gene may activate another gene, which activates another, and down the line until the far downstream result is increased RNA.

"Instead, to measure the direct genetic targets of p53, we measured not the water in the bucket, but the faucet dripping into it," Espinosa said.

The technique is called GRO-Seq, or Global Run-On Sequencing, and it measures new RNA being created, not overall RNA levels.

"Many teams around the world have been getting cancer cells, treating them with MDM2 inhibitors and waiting hours and hours to see what genes turn on and then only imprecisely. GRO-Seq lets us do it in minutes and the discoveries are massive," Espinosa said.

The technique also generates an astounding quantity of data. That's because it requires counting tens of thousands of RNA molecules before and after p53 activation.

So the experiment required designing algorithms -- sets of instructions for solving problems -- to sort through the data, and a computational biologist driving a supercomputer.

Espinosa partnered with computational biologist Robin Dowell at CU-Boulder's BioFrontiers Institute. Together they co-mentored a postdoctoral fellow, Mary Allen, who was capable of doing both the molecular biological and computational aspects of the work.

"The data collection took a year and the computational analysis took a year and a half," Dowell said.

The results helped the scientists pinpoint dozens of new genes directly regulated by p53, which may lead to future cancer-fighting strategies.

The technique of GRO-Seq also may have additional, far-reaching applications. For example, the Dowell lab plans to find RNAs whose synthesis is changed by a third copy of chromosome 21 in Down Syndrome individuals.

Mar. 31, 2015  A new population of 'memory' immune cells has been discovered by scientists, throwing light on what the body does when it sees a microbe for the second time. This insight, and others like it, will ... full story

Mar. 31, 2015  Coronary heart disease and stroke, two of the leading causes of death in the United States, are diseases associated with heightened platelet reactivity. A new study in humans suggests an underlying ... full story

Mar. 31, 2015  A new study had researchers seeking answers to why the therapeutic benefit afforded by SSRIs was so limited in children and teenagers. If researchers can uncover the biological mechanisms preventing ... full story

Mar. 31, 2015  A drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating bone disorder that that is present ... full story

Mar. 31, 2015  It is possible to quantify and classify the effects of different diseases on the activity of intestinal bacteria, new research demonstrates for the first time. Human intestinal flora, known as ... full story

Mar. 31, 2015  During prenatal development, the brains of most animals, including humans, develop specifically male or female characteristics. But scientists have known little about the details of how this ... full story

Mar. 31, 2015  A history of depression may put women at risk for developing diabetes during pregnancy, according to research. This study also pointed to how common depression is during pregnancy and the need for ... full story

Mar. 31, 2015  Women who are abused by their partner or ex-partner are much less likely to use contraception; this exposes them to sexually transmitted diseases and leads to more frequent unintended pregnancies and ... full story

Featured Videos

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015)  The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports.
Video provided by Reuters

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015)  Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline.
Video provided by Washington Post

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015)  Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17
Video provided by AFP

Related Stories

May 2, 2014  Mice lacking one copy of a gene called CTCF have abnormal DNA methylation and are markedly predisposed to cancer, new research demonstrates. CTCF is a very well-studied DNA binding protein that ... full story

Oct. 17, 2011  Researchers have discovered that a gene -- known as an androgen receptor (AR) -- is found in both prostate and breast cancers yet has opposite effects on these diseases. In prostate cancer, the AR ... full story

Aug. 15, 2011  Low oxygen can silence the BRCA1 tumor suppressor gene and contribute to the progression of cancer, according to a new study. Silencing this particular gene is one of the steps on the malignant ... full story

May 5, 2011  Scientists have identified the Aurora A gene -- which is vital for tumor growth and known to be expressed at higher-than-normal levels in many cancers -- as a target for potential therapies for ... full story

Jan. 26, 2011  Scientists are reporting discovery of a potential biochemical basis for the apparent cancer-fighting ability of broccoli and its veggie cousins. They found for the first time that certain substances ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.